Science & Enterprise subscription

Donate to our blog

Your support will help Science & Enterprise continue to provide science news for business people and business news for scientists.

Patent Office Decides for Broad and Editas in Crispr Case

The U.S. Patent and Trademark Office decided that the gene editing processes developed by Broad Institute and licensed to Editas Medicine do not interfere with techniques for genome editing created by University of California at Berkeley. . . . → Read More: Patent Office Decides for Broad and Editas in Crispr Case

Tissue Regeneration Start-Up Gains $33M in Early Funds

A new enterprise founded by researchers at Stanford University aims to discover and develop drugs that repair and regenerate tissue from stem cells. . . . → Read More: Tissue Regeneration Start-Up Gains $33M in Early Funds

Biotechs License Solid Tumor Therapy in $2.1B Deal

Biotechnology enterprise Immunomedics Inc. is licensing its enhanced antibody-based treatment for solid tumor cancers to Seattle Genetics, a developer of similar cancer drugs. . . . → Read More: Biotechs License Solid Tumor Therapy in $2.1B Deal

Univ. Spin-Off Offering Pediatric Care Software

A company spun-off from Indiana University is marketing software written in its medical school to relate pediatric clinical guidelines to parents’ concerns during office visits. . . . → Read More: Univ. Spin-Off Offering Pediatric Care Software

Protein Drug Discovery Company Launches, Gains $50M

A biotechnology enterprise founded by faculty at Scripps Research Institute plans to discover new therapies based on complex interactions with human proteins. . . . → Read More: Protein Drug Discovery Company Launches, Gains $50M

Simpler Lab Cell Production Techniques Devised

A process is being developed that makes it easier to produce healthy and diseased cells in the lab from human specimens for regenerative medicine and research. . . . → Read More: Simpler Lab Cell Production Techniques Devised

Scripps, Pfizer Collaborate on DNA-Coded Drug Discovery

Drug maker Pfizer Inc. is gaining access to advances in a synthetic chemistry technology developed by Scripps Research Institute that tags compounds with DNA identifiers. . . . → Read More: Scripps, Pfizer Collaborate on DNA-Coded Drug Discovery

Sanofi Licensing Antibody for Autoimmune Diseases

The global drug company Sanofi is licensing a synthetic antibody to treat autoimmune disorders being developed by a spin-off enterprise from Dartmouth College. . . . → Read More: Sanofi Licensing Antibody for Autoimmune Diseases

Ionis Options Cardiac Drugs in $1.5 Billion Deal

Biotechnology company Ionis Pharmaceuticals is providing drug maker Novartis first access to two experimental drugs for controlling proteins that promote cholesterol and triglycerides, which contribute to heart disease. . . . → Read More: Ionis Options Cardiac Drugs in $1.5 Billion Deal

Spin-Off Creates Enzyme to Prevent Celiac Disease

A spin-off enterprise from University of Washington is developing a synthetic enzyme that prevents dietary gluten from triggering symptoms of celiac disease. . . . → Read More: Spin-Off Creates Enzyme to Prevent Celiac Disease